We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-19.28%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$85.9M
AUM Growth
-$17.7M
Cap. Flow
+$10.3M
Cap. Flow %
11.97%
Top 10 Hldgs %
58.4%
Holding
67
New
17
Increased
15
Reduced
14
Closed
19

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.49M
2
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$4.89M
3
ZYXI
Zynex
ZYXI
+$3.73M
4
ATRS
Antares Pharma, Inc.
ATRS
+$2.94M
5
VCEL icon
Vericel Corp
VCEL
+$2.53M

Top Sells

Rank Stock Value
1
WMGI
Wright Medical Group Inc
WMGI
+$6.91M
2
AGN
Allergan plc
AGN
+$2.62M
3
DERM
Dermira, Inc.
DERM
+$2.5M
4
HUM icon
Humana
HUM
+$2.13M
5
BPMC
Blueprint Medicines
BPMC
+$2.11M

Sector Composition

Rank Sector Weight
1 Healthcare 97.9%
2 Real Estate 1.33%
3 Communication Services 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXGN icon
26
Axogen
AXGN
$2.38B
$781K 0.91%
75,050
-52,400
-41% -$667K
TPST icon
27
Tempest Therapeutics
TPST
$14.4M
$778K 0.91%
+756
New +$1.1M
PTCT icon
28
PTC Therapeutics
PTCT
$5.91B
$727K 0.85%
16,300
+9,500
+140% +$478K
CRSP icon
29
CRISPR Therapeutics
CRSP
$4.99B
$696K 0.81%
16,400
-5,900
-26% -$305K
FOLD
30
DELISTED
Amicus Therapeutics
FOLD
$665K 0.77%
72,000
-116,800
-62% -$1.11M
CNST
31
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$563K 0.66%
17,900
-24,200
-57% -$841K
ENTA icon
32
Enanta Pharmaceuticals
ENTA
$388M
$545K 0.63%
+10,600
New +$565K
CTSO icon
33
Cytosorbents Corp
CTSO
$25M
$538K 0.63%
+69,600
New +$351K
LVGO
34
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$516K 0.6%
18,100
+1,234
+7% +$32K
SWAV
35
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$404K 0.47%
12,185
+6,785
+126% +$269K
NVCR icon
36
NovoCure
NVCR
$1.83B
$377K 0.44%
+5,597
New +$442K
RLMD icon
37
Relmada Therapeutics
RLMD
$564M
$375K 0.44%
+11,000
New +$443K
AMRN
38
Amarin Corp
AMRN
$301M
$360K 0.42%
+4,500
New +$1.5M
STAA icon
39
STAAR Surgical
STAA
$1.15B
$252K 0.29%
7,798
-28,142
-78% -$948K
TCRR
40
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$237K 0.28%
+30,624
New +$375K
PCRX icon
41
Pacira BioSciences
PCRX
$1.02B
$235K 0.27%
+7,000
New +$291K
SNDX icon
42
Syndax Pharmaceuticals
SNDX
$1.76B
$230K 0.27%
20,980
– –
KDNY
43
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$222K 0.26%
+16,240
New +$192K
AYTU icon
44
AYTU BioPharma
AYTU
$25M
$209K 0.24%
+698
New +$135K
VNDA icon
45
Vanda Pharmaceuticals
VNDA
$308M
$197K 0.23%
+19,000
New +$236K
RVNC
46
DELISTED
Revance Therapeutics, Inc.
RVNC
$176K 0.2%
11,869
-11,331
-49% -$234K
XENE icon
47
Xenon Pharmaceuticals
XENE
$6.24B
$150K 0.17%
13,228
-148,372
-92% -$2.11M
ARGX icon
48
argenx
ARGX
$54.8B
– –
-1,500
Closed -$240K
ARVN icon
49
Arvinas
ARVN
$560M
– –
-8,700
Closed -$357K
BPMC
50
DELISTED
Blueprint Medicines
BPMC
– –
-26,400
Closed -$2.11M
1
2
3

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Soleus Capital Management held 67 positions worth $85.9M, down 17% from $104M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Soleus Capital Management deployed $10.3M of net new capital in Q1 2020, opening 17 new positions and adding to 15 existing holdings. Its largest new stake was Zynex: 383,420 shares worth $3.86M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Real Estate and Communication Services.

On the sell side, the largest reduction was Allergan plc, an estimated $2.62M trimmed.

  • Soleus Capital Management's largest Q1 2020 buy was Zynex: 383,420 shares worth $3.86M.
  • Soleus Capital Management added most to IVERIC bio, Inc. Common Stock in Q1 2020, an estimated $5.49M increase.
  • Soleus Capital Management's biggest Q1 2020 reduction was Allergan plc, cutting an estimated $2.62M.
  • Soleus Capital Management fully exited Wright Medical Group Inc in Q1 2020, selling an estimated $6.91M.
  • Soleus Capital Management's ten largest holdings make up 58% of its $85.9M portfolio in Q1 2020.
  • Soleus Capital Management opened 17 new positions and closed 19 in Q1 2020.
  • Soleus Capital Management's portfolio value fell 17% quarter-over-quarter to $85.9M.

Based on Soleus Capital Management's 13F filing for Q1 2020, filed 15 May 2020.